188Re-SSS/Lipiodol is an analogue of 188Re-HDD/Lipiodol, a therapeutic in form of a mixture of ethyl esters of iodinated fatty acids of poppy seed oil (Lipiodol™) and a complex of radioactive rhenium that is soluble in this oil. The molecule is under development for the treatment of hepatocarcinoma with Portal Vein Thrombosis, non-resectable and untransplantable (radioembolization). This molecule completed a Phase I trial in 2022.
Target/Mechanism: Fatty acid containing tissues
Carrier/Ligand: Lipiodol
Radiation Type: beta electrons (β–)